Omapro would be the first treatment for chronic myeloid leukemia patients with the T315I genetic mutation that makes them resistant to existing treatments ...
... that several distinct mutations found in a subset of patients with acute myelogenous leukemia (AML) result in excess production of the same metabolite. ...
Wall Street Journal (blog) - Jacob Goldstein - 12 hours ago
... using Novartis's Tasigna or Bristol-Myers Squibb's Sprycel for patients who have chronic myeloid leukemia and are resistant to Novartis's Gleevec. ...
... a proposed ChemGenex Pharmaceuticals Ltd. (CXSPY, $11.00, +$0.25, +2.33%) drug to treat certain type of patients with chronic myeloid leukemia was "low. ...